<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03000634</url>
  </required_header>
  <id_info>
    <org_study_id>204814</org_study_id>
    <nct_id>NCT03000634</nct_id>
  </id_info>
  <brief_title>2015-09: A Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy</brief_title>
  <official_title>2015-09: A Phase II Randomized, Open-label Study of Anti-SLAMF7 mAb During Maintenance Therapy Versus Standard Maintenance Therapy in Gene Expression Profiling (GEP)- Defined Low Risk Multiple Myeloma Patients With High Risk Cytogenetic Abnormalities</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arkansas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Arkansas</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare the effectiveness and safety of maintenance therapy with continuous&#xD;
      bortezomib, lenalidomide, and dexamethasone (VRD) compared to maintenance therapy that&#xD;
      alternates VRD with Elotuzumab, lenalidomide, and dexamethasone (Elo RD) every eight weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Past studies conducted at the Myeloma Institute have shown that many patients with low-risk&#xD;
      disease (as determined by gene array studies - studies that look at specific genes using&#xD;
      special equipment) respond very well to treatment. However, about 15% of low-risk patients&#xD;
      still relapse during the first three years of treatment, which means that better treatments&#xD;
      are still needed.&#xD;
&#xD;
      This study will compare the effectiveness and safety of maintenance therapy with continuous&#xD;
      bortezomib, lenalidomide, and dexamethasone (VRD) compared to maintenance therapy that&#xD;
      alternates VRD with Elotuzumab, lenalidomide, and dexamethasone (Elo RD) every eight weeks.&#xD;
&#xD;
      Elotuzumab, bortezomib, lenalidomide and dexamethasone are all approved by the FDA for the&#xD;
      treatment of patients with multiple myeloma. VRD is the standard maintenance regimen&#xD;
      prescribed at the University of Arkansas for Medical Sciences (UAMS) Myeloma Institute for&#xD;
      patients with low risk disease. The investigators want to learn if alternating VRD with Elo&#xD;
      RD during maintenance therapy will result in better outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study was not and will not be initiated due to lack of funding.&#xD;
  </why_stopped>
  <start_date type="Anticipated">May 2017</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients without disease progression within 36 months from start of study treatment.</measure>
    <time_frame>36 months</time_frame>
    <description>Progression-Free Survival (PFS)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Anti-SLAMF7 mAb+RD alternating every 8 wks with VRD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Elotuzumab 10 mg day 1,15 Lenalidomide 25 mg day 1-21 Dexamethasone 20 mg day 1,8,15,22 Bortezomib 1.3 mg day 1,8,15</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VRD-bortezomib, lenalidomide, dexamethasone</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Bortezomib 1.3 mg day 1, 8,15 Lenalidomide 25 mg day 1-21 Dexamethasone 20 mg day 1, 8,15,22</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elotuzumab</intervention_name>
    <description>Administered through a small tube that goes directly into the vein</description>
    <arm_group_label>Anti-SLAMF7 mAb+RD alternating every 8 wks with VRD</arm_group_label>
    <other_name>Elo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>Administered as a subcutaneous injection under the skin</description>
    <arm_group_label>Anti-SLAMF7 mAb+RD alternating every 8 wks with VRD</arm_group_label>
    <arm_group_label>VRD-bortezomib, lenalidomide, dexamethasone</arm_group_label>
    <other_name>Velcade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Capsule taken by mouth</description>
    <arm_group_label>Anti-SLAMF7 mAb+RD alternating every 8 wks with VRD</arm_group_label>
    <arm_group_label>VRD-bortezomib, lenalidomide, dexamethasone</arm_group_label>
    <other_name>Revlimid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>Taken by mouth</description>
    <arm_group_label>Anti-SLAMF7 mAb+RD alternating every 8 wks with VRD</arm_group_label>
    <arm_group_label>VRD-bortezomib, lenalidomide, dexamethasone</arm_group_label>
    <other_name>Decadron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must be at least 18 years of age and not older than 75 years of age at the&#xD;
             time of enrollment.&#xD;
&#xD;
          -  Patients must have completed a Total Therapy-like treatment regimen for newly&#xD;
             diagnosed multiple myeloma consisting of induction chemotherapy and stem cell&#xD;
             transplant within 4 months of study enrollment. The completed regimen may have also&#xD;
             included post-transplant consolidation therapy, but post-transplant consolidation is&#xD;
             not required. The regimen must have included, at minimum, a proteasome inhibitor, an&#xD;
             immunomodulatory agent, and a corticosteroid.&#xD;
&#xD;
          -  Patients must have low-risk disease, defined as an existing myeloma prognostic risk&#xD;
             score risk score &lt; 50.4 from a prior bone marrow biopsy sample in which plasma cells&#xD;
             were present.&#xD;
&#xD;
          -  Patients must have high risk cytogenetic abnormalities, defined as one or more of the&#xD;
             following chromosomal aberrations detected by fluorescent in situ hybridization: 17p-,&#xD;
             1q+, t(4;14) and t(14;16).&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group ≤ 2, unless solely due to symptoms of multiple&#xD;
             myeloma-related bone disease.&#xD;
&#xD;
          -  Patients must have absolute neutrophil count(ANC) ≥ 1,000/mm3 and a platelet count of&#xD;
             ≥ 100,000/µL, unless lower levels are due to extensive bone marrow plasmacytosis.&#xD;
&#xD;
          -  Patients must have a baseline serum creatinine level of &lt; 3 mg/dL and baseline alanine&#xD;
             aminotransferase (ALT) &lt; 3x Upper limit of normal (ULN)&#xD;
&#xD;
          -  Toxicities related to prior therapies must be resolved to ≤ Grade 2 according to NCI&#xD;
             Common Terminology for Adverse Events (CTCAE) Version 4.&#xD;
&#xD;
          -  Female patients must be:&#xD;
&#xD;
               -  Postmenopausal for at least 1 year before the screening visit, OR&#xD;
&#xD;
               -  Surgically sterile, OR&#xD;
&#xD;
               -  If they are of childbearing potential, agree to practice 2 simultaneous effective&#xD;
                  methods of contraception, from the time of signing the informed consent form&#xD;
                  through 90 days after the last dose of study drug, OR&#xD;
&#xD;
               -  Agree to practice true abstinence when this is in line with the preferred and&#xD;
                  usual lifestyle of the subject. (Periodic abstinence [eg, calendar, ovulation,&#xD;
                  symptothermal, post-ovulation methods] and withdrawal are not acceptable methods&#xD;
                  of contraception.)&#xD;
&#xD;
          -  Male patients, even if surgically sterilized (ie, post-vasectomy) must agree to one of&#xD;
             the following:&#xD;
&#xD;
               -  Practice effective barrier contraception during the entire study treatment period&#xD;
                  and through 90 days after the last dose of study drug, OR&#xD;
&#xD;
               -  Practice true abstinence when this is in line with the preferred and usual&#xD;
                  lifestyle of the subject. (Periodic abstinence [eg, calendar, ovulation,&#xD;
                  symptothermal, post-ovulation methods] and withdrawal are not acceptable methods&#xD;
                  of contraception.)&#xD;
&#xD;
          -  Patients must sign an IRB-approved informed consent indicating their understanding of&#xD;
             the proposed treatment and understanding that the protocol has been approved by the&#xD;
             Institutional Review Board (IRB).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female patients who are nursing or pregnant may not participate.&#xD;
&#xD;
          -  Women of childbearing potential must have a negative pregnancy documented within one&#xD;
             week of beginning study treatment. Refer to the Revlimid Risk Evaluation and&#xD;
             Management Strategy (REMS) program for more information.&#xD;
&#xD;
          -  History of poorly controlled hypertension, diabetes mellitus, active or uncontrolled&#xD;
             hepatitis, or other serious medical or psychiatric illness that could potentially&#xD;
             interfere with the completion of treatment according to this protocol, or that in the&#xD;
             opinion of the investigator would constitute a hazard for participating in this study.&#xD;
&#xD;
          -  Known Chronic obstructive pulmonary disease with a Forced Expiratory Volume in 1&#xD;
             second (FEV1) less than 50% of predicted normal. Note that FEV1(forced expiratory&#xD;
             volume in 1 second) testing is required for patients suspected of having chronic&#xD;
             obstructive pulmonary disease.&#xD;
&#xD;
          -  Clinically significant cardiac disease, including: myocardial infarction within one&#xD;
             year prior to study enrollment or history of unstable or uncontrolled&#xD;
             disease/condition related to or affecting cardiac function (e.g., unstable angina,&#xD;
             congestive heart failure, New York Heart Association Class III-IV); cardiac arrhythmia&#xD;
             ≥ Grade 2 or clinical significant electrocardiogram abnormalities.&#xD;
&#xD;
          -  Prior malignancy, except for adequately treated basal cell or squamous cell skin&#xD;
             cancer, in situ cervical cancer, or other cancer for which the patient has not&#xD;
             received treatment for one year prior to enrollment. Other cancers will be acceptable&#xD;
             if the patient's life expectancy exceeds five years.&#xD;
&#xD;
          -  Known allergies, hypersensitivity, or intolerance to monoclonal antibodies or human&#xD;
             proteins or any of the study medications, their analogues, or excipients in the&#xD;
             various formulations of any agent (refer to the latest versions of the package&#xD;
             inserts).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Faith E Davies, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arkansas for Medical Science-Myeloma Institute</affiliation>
  </overall_official>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>December 7, 2016</study_first_submitted>
  <study_first_submitted_qc>December 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2016</study_first_posted>
  <last_update_submitted>April 12, 2017</last_update_submitted>
  <last_update_submitted_qc>April 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Elotuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03000634
org study id: 204814
nct id: NCT03000634
lead sponsor: 
has dmc: Yes
is fda regulated drug: Yes
is fda regulated device: No
This study will compare the effectiveness and safety of maintenance therapy with continuous
      bortezomib, lenalidomide, and dexamethasone (VRD) compared to maintenance therapy that
      alternates VRD with Elotuzumab, lenalidomide, and dexamethasone (Elo RD) every eight weeks.
Past studies conducted at the Myeloma Institute have shown that many patients with low-risk
      disease (as determined by gene array studies - studies that look at specific genes using
      special equipment) respond very well to treatment. However, about 15% of low-risk patients
      still relapse during the first three years of treatment, which means that better treatments
      are still needed.

      This study will compare the effectiveness and safety of maintenance therapy with continuous
      bortezomib, lenalidomide, and dexamethasone (VRD) compared to maintenance therapy that
      alternates VRD with Elotuzumab, lenalidomide, and dexamethasone (Elo RD) every eight weeks.

      Elotuzumab, bortezomib, lenalidomide and dexamethasone are all approved by the FDA for the
      treatment of patients with multiple myeloma. VRD is the standard maintenance regimen
      prescribed at the University of Arkansas for Medical Sciences (UAMS) Myeloma Institute for
      patients with low risk disease. The investigators want to learn if alternating VRD with Elo
      RD during maintenance therapy will result in better outcomes.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Percentage of patients without disease progression within 36 months from start of study treatment.
time frame: 36 months
description: Progression-Free Survival (PFS)
arm group label: Anti-SLAMF7 mAb+RD alternating every 8 wks with VRD
arm group type: Experimental
description: Elotuzumab 10 mg day 1,15 Lenalidomide 25 mg day 1-21 Dexamethasone 20 mg day 1,8,15,22 Bortezomib 1.3 mg day 1,8,15
arm group label: VRD-bortezomib, lenalidomide, dexamethasone
arm group type: Other
description: Bortezomib 1.3 mg day 1, 8,15 Lenalidomide 25 mg day 1-21 Dexamethasone 20 mg day 1, 8,15,22
intervention type: Drug
intervention name: Elotuzumab
description: Administered through a small tube that goes directly into the vein
arm group label: Anti-SLAMF7 mAb+RD alternating every 8 wks with VRD
other name: Elo
intervention type: Drug
intervention name: Bortezomib
description: Administered as a subcutaneous injection under the skin
arm group label: Anti-SLAMF7 mAb+RD alternating every 8 wks with VRD
arm group label: VRD-bortezomib, lenalidomide, dexamethasone
other name: Velcade
intervention type: Drug
intervention name: Lenalidomide
description: Capsule taken by mouth
arm group label: Anti-SLAMF7 mAb+RD alternating every 8 wks with VRD
arm group label: VRD-bortezomib, lenalidomide, dexamethasone
other name: Revlimid
intervention type: Drug
intervention name: Dexamethasone
description: Taken by mouth
arm group label: Anti-SLAMF7 mAb+RD alternating every 8 wks with VRD
arm group label: VRD-bortezomib, lenalidomide, dexamethasone
other name: Decadron
criteria: 
gender: All
minimum age: 18 Years
maximum age: 75 Years
healthy volunteers: No
last name: Faith E Davies, MD
role: Principal Investigator
affiliation: University of Arkansas for Medical Science-Myeloma Institute
responsible party type: Sponsor
mesh term: Multiple Myeloma
mesh term: Neoplasms, Plasma Cell
mesh term: Dexamethasone
mesh term: Lenalidomide
mesh term: Bortezomib
mesh term: Elotuzumab
sharing ipd: No